الفهرس 
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
Historically, vascular involvement was accepted as a sign of un-resectability for PDAC. However, studies since the early 1990s have shown equivalent survival of patients undergoing margin negative venous resection to patients undergoing standard pancreaticoduodenectomy (PD) and superior to locally advanced disease treated without surgical resection [3-5]. Development of newer vascular reconstruction techniques and improvements in neoadjuvant therapies has now made patients with limited vascular involvement potentially resectable [6, 7]. Between 2008 and 2014, 254 patients with borderline resectable pancreatic cancer who went to the operative theatre for planned resection in Johns Hopkins Hospital were enrolled in our study. Patients’ CT angiographic imaging were re-reviewed to describe the degree of vascular involvement according to predetermined radiologic key descriptors. In order to compare the histopathologic outcomes in BRPC patients who received neoadjuvant therapy prior to surgical resection to those who underwent upfront surgery, detailed pathologic results were recorded from histology reports including TNM pathological staging which was applied according to TNM staging published by the American Joint Committee on Cancer (6th edition) [216, 217].